Agathe Dubuisson
A5039469080- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Cancer Immunotherapy and Biomarkers
- Bladder and Urothelial Cancer Treatments
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses
- Long-Term Effects of COVID-19
- Urinary and Genital Oncology Studies
- vaccines and immunoinformatics approaches
- RNA Interference and Gene Delivery
- Cell death mechanisms and regulation
- Immune cells in cancer
- Tryptophan and brain disorders
- Hepatitis C virus research
- Immune responses and vaccinations
- COVID-19 and healthcare impacts
- Pancreatic and Hepatic Oncology Research
- Cancer Research and Treatments
- S100 Proteins and Annexins
- Monoclonal and Polyclonal Antibodies Research
- Biological Research and Disease Studies
- Phagocytosis and Immune Regulation
- Cancer therapeutics and mechanisms
- Metabolomics and Mass Spectrometry Studies
- interferon and immune responses
Servier (France)
2024
Columbia University Irving Medical Center
2024
Université Paris-Saclay
2024
La Ligue Contre le Cancer
2020-2022
Inserm
2017-2022
Institut Gustave Roussy
2020-2022
Université Bourgogne Franche-Comté
2017-2019
Centre de recherche Translationnelle en Médecine moléculaire
2019
Covalab (France)
2017
Abstract The circulating metabolome provides a snapshot of the physiological state organism responding to pathogenic challenges. Here we report alterations in plasma reflecting clinical presentation COVID-19 patients with mild (ambulatory) diseases, moderate disease (radiologically confirmed pneumonitis, hospitalization and oxygen therapy), critical (in intensive care). This analysis revealed major disease- stage-associated shifts metabolome, meaning that at least 77 metabolites including...
Abstract Biomarkers guiding the neoadjuvant use of immune-checkpoint blockers (ICB) are needed for patients with localized muscle-invasive bladder cancers (MIBC). Profiling tumor and blood samples, we found that follicular helper CD4+ T cells (TFH) among best therapeutic targets pembrolizumab correlating progression-free survival. TFH were associated tumoral CD8 PD-L1 expression at baseline induction tertiary lymphoid structures after pembrolizumab. Blood central memory accumulated in tumors...
Patients with cancer are at higher risk of severe coronavirus infectious disease 2019 (COVID-19), but the mechanisms underlying virus-host interactions during therapies remain elusive. When comparing nasopharyngeal swabs from and noncancer patients for RT-qPCR cycle thresholds measuring acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in 1063 (58% cancer), we found that malignant favors magnitude duration viral RNA shedding concomitant prolonged serum elevations type 1 IFN...
Background The Mixed Lymphocyte Reaction (MLR) consists in the allogeneic co-culture of monocytes derived dendritic cells (MoDCs) with T from another donor. This vitro assay is largely used for assessment immunotherapy compounds. Nevertheless, phenotypic changes associated lymphocyte responsiveness under MLR have never been thoroughly evaluated. Methods Here, we multiplex cytokine and chemokine assays, multiparametric flow cytometry single cell RNA sequencing to deeply characterize...
Background The ability of immune cells to rapidly respond pathogens or malignant is tightly linked metabolic pathways. In cancer, the tumor microenvironment (TME) represents a complex system with strong metabolism stress, in part due glucose shortage, which limits proper T cell activation, differentiation and functions preventing anti-tumor immunity. Methods this study, we evaluated reactivity glucose-restricted mixed lymphocyte reaction (MLR), using comprehensive profiling soluble factors,...
Abstract Vaccination against coronavirus disease 2019 (COVID-19) relies on the in-depth understanding of protective immune responses to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). We characterized polarity and specificity memory T cells directed SARS-CoV-2 viral lysates peptides determine correlates with spontaneous, virus-elicited, or vaccine-induced protection COVID-19 in disease-free cancer-bearing individuals. A disbalance between type 1 2 cytokine release was...
Report29 December 2020Open Access Source DataTransparent process Immunodynamics of explanted human tumors for immuno-oncology Agathe Dubuisson orcid.org/0000-0002-7526-0769 Institut Gustave Roussy, Villejuif, France National de la Santé Et Recherche Médicale (INSERM) U1015, Equipe Labellisée—Ligue Nationale contre le Cancer, FranceThese authors contributed equally to this work as first Search more papers by author Jean-Eudes Fahrner orcid.org/0000-0001-6581-8418 Transgene S.A,...
Aging | doi:10.18632/aging.203525. Mélanie Bourgin, Lisa Derosa, Carolina Alves Costa Silva, Anne-Gaëlle Goubet, Agathe Dubuisson, François-Xavier Danlos, Claudia Grajeda-Iglesias, Luigi Cerbone, Arthur Geraud, Ariane Laparra, Fanny Aprahamian, Nitharsshini Nirmalathasan, Frank Madeo, Laurence Zitvogel, Guido Kroemer, Sylvère Durand
Abstract Patients with cancer are at higher risk of severe coronavirus infectious disease 2019 (COVID-19), but the mechanisms underlying virus-host interactions during therapies remain elusive. When comparing nasopharyngeal swabs from and non-cancer patients for RT-qPCR cycle thresholds measuring acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in 1063 (58% cancer, 89% COVID-19 + ), we found that malignant favors magnitude duration viral RNA shedding concomitant prolonged serum...
Development of therapeutic antibodies in oncology has attracted much interest the past decades. More than 30 them have been approved and are being used to treat patients suffering from cancer. Despite encouraging results, albeit most clinical trials aiming at evaluating monoclonal directed against TRAIL agonist receptors discontinued, DR4 or DR5 remain interesting targets, since these overexpressed by tumour cells able trigger their death. In an effort develop novel specific anti-DR4...
<div>Abstract<p>Vaccination against coronavirus disease 2019 (COVID-19) relies on the in-depth understanding of protective immune responses to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). We characterized polarity and specificity memory T cells directed SARS-CoV-2 viral lysates peptides determine correlates with spontaneous, virus-elicited, or vaccine-induced protection COVID-19 in disease-free cancer-bearing individuals. A disbalance between type 1 2 cytokine...
<div>Abstract<p>Biomarkers guiding the neoadjuvant use of immune-checkpoint blockers (ICB) are needed for patients with localized muscle-invasive bladder cancers (MIBC). Profiling tumor and blood samples, we found that follicular helper CD4<sup>+</sup> T cells (T<sub>FH</sub>) among best therapeutic targets pembrolizumab correlating progression-free survival. T<sub>FH</sub> were associated tumoral CD8 PD-L1 expression at baseline induction...
<div>Abstract<p>Biomarkers guiding the neoadjuvant use of immune-checkpoint blockers (ICB) are needed for patients with localized muscle-invasive bladder cancers (MIBC). Profiling tumor and blood samples, we found that follicular helper CD4<sup>+</sup> T cells (T<sub>FH</sub>) among best therapeutic targets pembrolizumab correlating progression-free survival. T<sub>FH</sub> were associated tumoral CD8 PD-L1 expression at baseline induction...
Supplementary Figure from <i>Escherichia coli</i>–Specific CXCL13-Producing T<sub>FH</sub> Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer
Supplementary Figure from <i>Escherichia coli</i>–Specific CXCL13-Producing T<sub>FH</sub> Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer
<div>Abstract<p>Vaccination against coronavirus disease 2019 (COVID-19) relies on the in-depth understanding of protective immune responses to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). We characterized polarity and specificity memory T cells directed SARS-CoV-2 viral lysates peptides determine correlates with spontaneous, virus-elicited, or vaccine-induced protection COVID-19 in disease-free cancer-bearing individuals. A disbalance between type 1 2 cytokine...
Supplementary Data from The Polarity and Specificity of Antiviral T Lymphocyte Responses Determine Susceptibility to SARS-CoV-2 Infection in Patients with Cancer Healthy Individuals